Crescent Biopharma (CBIO) Non Operating Income (2013 - 2026)
Crescent Biopharma (CBIO) reported Non Operating Income of $1.4 million for Q1 2026, up 256.49% year-over-year from $405617.5 in Q1 2025, and up 607.37% quarter-over-quarter from -$285000.0 in Q4 2025.
Crescent Biopharma (CBIO) Non Operating Income (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has 10 years of Non Operating Income data on file, last reported at $1.4 million in Q1 2026.
- Non Operating Income for Q1 2026 came in at $1.4 million, up 256.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (up 535.52% YoY), and the FY2025 annual result was -$690000.0, down 131.94% from the prior year.
- Non Operating Income climbed to $1.4 million in Q1 2026 per CBIO's latest filing, from -$285000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $1.4 million in Q1 2026 and troughed at -$924000.0 in Q1 2025.
- A 4-year average of $319271.5 and a median of $561586.0 in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2025 and 2026: Non Operating Income plunged 142.16% in 2025, then surged 256.49% in 2026.
- A 4-year view of Non Operating Income shows it stood at $512194.0 in 2023, then jumped by 31.98% to $676000.0 in 2024, then sank by 142.16% to -$285000.0 in 2025, then surged by 607.37% to $1.4 million in 2026.
- Business Quant data shows CBIO's Non Operating Income at $1.4 million in Q1 2026, -$285000.0 in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Crescent Biopharma | 486.92 Mn | 297.76 Mn | - | 1.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.45 Mn |
| Dec 31, 2025 | -285,000.00 |
| Sep 30, 2025 | 1.28 Mn |
| Jun 30, 2025 | -760,000.00 |
| Mar 31, 2025 | -924,000.00 |
| Dec 31, 2024 | 676,000.00 |
| Dec 31, 2023 | 512,194.00 |
| Sep 30, 2023 | 610,978.00 |
| Sep 30, 2018 | 944,409.00 |
| Jun 30, 2018 | 870,139.00 |
| Mar 31, 2018 | 363,704.00 |
| Dec 31, 2017 | 278,004.00 |
| Sep 30, 2017 | 231,634.00 |
| Jun 30, 2017 | 102,079.00 |
| Mar 31, 2017 | 39,495.00 |
| Dec 31, 2016 | 29,673.00 |
| Sep 30, 2016 | 32,063.00 |
| Jun 30, 2016 | 21,813.00 |
| Mar 31, 2016 | 20,097.00 |
| Dec 31, 2015 | 5,823.00 |